Elafibranor

Chemical formula: C₂₂H₂₄O₄S  Molecular mass: 384.14 g/mol  PubChem compound: 9864881

Therapeutic indications

Elafibranor is indicated for:

Primary biliary cholangitis

Population group: only adults (18 years old or older)

Elafibranor is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Elafibranor is contraindicated in the following cases:

Lactation

Lactation

Pregnancy

Pregnancy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2024: IQIRVO Film-coated tablet
Summary of Product Characteristics (SPC) 2024: IQIRVO Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈